Development of New Businesses in Home Healthcare and Nursing and Welfare Services
First written in FY2016-Q3. 7 of 12 entries say "Advanced", first in FY2016. Latest entry: FY2019.
0 other companies' latest entry also says "Dropped".
- FY2019DroppedAnnual report
「At a meeting of the Board of Directors held on 15 March 2019, the Company resolved to transfer the duranta business to 株式会社ZAIKEN.」
The full-year report also confirmed that the Company entered into an agreement to transfer the duranta business to 株式会社ZAIKEN on 18 March 2019 and transferred the business on the same date. - FY2019-Q2DroppedAnnual report
「The business environment changed amid structural changes in the home healthcare industry and price competition with other companies. Since sales began in 2014, performance has remained below the initial budget by a wide margin because of poor results, and the business has continued to be unprofitable. ...The Company decided to transfer the duranta business.」
The duranta business was transferred to 株式会社ZAIKEN on 18 March 2019 because of continuing weak performance and unprofitability. The Company ended its in-house operation of the business as a new business in the home healthcare and social care fields. - FY2018AdvancedAnnual report
「The duranta business, which began as a new business in the home healthcare and social care fields, aimed to expand its business scope as a wearable electrocardiograph for arrhythmia testing. Development incorporating arrhythmia analysis software progressed, and shipments began in January 2018. As its scope expanded from home healthcare and social care into cardiovascular medicine, progress exceeded the results of the previous year.」
The product incorporating arrhythmia analysis software began shipping in January 2018. The report noted expansion from the home healthcare and social care fields into cardiovascular medicine and progress exceeding the results of the previous year. - FY2018-Q3AdvancedAnnual report
「The duranta business, which began as a new business in the home healthcare and social care fields, aimed to expand its business scope as a wearable electrocardiograph for arrhythmia testing. Development incorporating arrhythmia analysis software progressed, and shipments began in January 2018. As its scope expanded from home healthcare and social care into cardiovascular medicine, progress exceeded the results of the previous year.」
Following development incorporating arrhythmia analysis software, duranta began shipping in January 2018. The report noted expansion from the home healthcare and social care fields into cardiovascular medicine and progress exceeding the results of the previous year. - FY2018-Q2AdvancedAnnual report
「With a view to developing a new business in the cardiovascular field, the wearable electrocardiograph for arrhythmia testing, duranta, for which software development and approval for insurance coverage had been obtained, began shipping in the second quarter.」
For duranta, following software development and approval for insurance coverage, actual shipments began in the second quarter. Expansion from the home healthcare and social care fields into cardiovascular medicine was also progressing. - FY2018-Q1AdvancedAnnual report
「With a view to developing a new business in the cardiovascular field, the wearable electrocardiograph for arrhythmia testing, duranta, for which software development and approval for insurance coverage had been obtained, was ready for preparations to actively expand shipments planned from the second quarter.」
For duranta, the Company obtained approval for insurance coverage in addition to completing software development, and progressed to the stage of completing preparations to expand shipments from the second quarter. - FY2017AdvancedAnnual report
「The duranta business, which began as a new business in the home healthcare and social care fields, aimed to expand its business scope as a wearable electrocardiograph for arrhythmia testing. The Company focused on software development and procedures including an application for insurance coverage in preparation for the start of sales, and expected to begin generating revenue from the fiscal year ending September 2018.」
For duranta, the Company proceeded with software development and an application for insurance coverage to expand into wearable electrocardiographs for the cardiovascular field, and expected revenue generation to begin in the fiscal year ending September 2018. - FY2017-Q3AdvancedAnnual report
「Although the launch was delayed from the originally planned second quarter, the Company launched its own portal site, Dr.TIMES, the name of the website, in June of the third quarter.」
In the reservation and search site business for private-pay medical services, the project progressed beyond the preparation stage, and the Company launched its own portal site, Dr.TIMES, in June of the third quarter. - FY2017-Q2RestatedAnnual report
「During the cumulative second quarter of the current consolidated fiscal year, the Company focused on preparations for launching a portal site that would serve as the core of its new business, while」
In the reservation and search site business for private-pay medical services, preparations for launching the portal site continued. - FY2017-Q1RestatedAnnual report
「During the cumulative first quarter of the current consolidated fiscal year, while focusing on preparations for the launch of the new company, the Company continued to develop its business with the following three priorities, as in the previous fiscal year: improving the competitiveness of products in the medical imaging business, developing new businesses in the home healthcare and social care fields, and reducing product costs.」
Development of new businesses in the home healthcare and social care fields continued to be listed as a priority measure from the previous fiscal year. - FY2016AdvancedAnnual report
「The duranta business aims to expand by developing distributors in the home healthcare and social care fields. Joint research with a university aimed at expanding into the cardiovascular field through arrhythmia diagnosis is under way, and preparations including obtaining the CE mark for expansion into Europe are progressing smoothly.」
Specific expansion measures and preparations were reported, including developing distributors, expanding into the cardiovascular field and preparing to obtain the CE mark for expansion into Europe. - FY2016-Q3First statedAnnual report
「Development of new businesses in the home healthcare and social care fields」
The Company has positioned the home healthcare and social care fields, including the duranta business, as areas for developing new businesses.